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INTRODUCTION
Screening programs based on cytological staining tech-
niques (Pap test) has led to a remarkable decline in incidence 
and mortality from invasive cervical cancer. However the Pap 
test efficacy is hampered by the high inter-observer variability 
and false negative/positive rates [1]. Even the “gold standard” 
histological assessment of cervical biopsies can be significant-
ly affected by the intra- and inter-observer inconsistencies. 
Novel markers potentially applied on cytological/histological 
specimens could improve the identification of lesions with 
increased risk for progression. p16
INK4a (p16) is a tumor sup-
pressor protein typically over-expressed in dysplastic and neo-
plastic cervix epithelium [1]. By means of a semi-quantitative 
analysis, several studies showed that high-grade lesions (cervi-
cal intraepithelial neoplasia [CIN] II to invasive cancer) exhibi-
ted a full-thickness and strong p16 immuno-staining [1-3]. 
However, a quantitative evaluation of p16 positive areas and 
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Objective: This study focused on comparing the expression levels of p16, Ki-67, and minichromosome maintenance 7 (MCM7) 
protein in normal and affected cervical epithelium to ascertain the biological significance of these markers in detecting 
progressive cervical disease.
Methods: A quantitative and based on-scanning-microscopy analysis of the three markers expression was performed in normal 
and cervical intraepithelial neoplasia (CIN) I, II, and III tissues. p16 area as well as p16, Ki-67, and MCM7 positive cells or nuclei 
were evaluated according to their distribution and extent through the cervical epithelium.
Results: A clear p16 over-expression was observed in all the dysplastic epithelium tissue samples. The quantitative analysis of 
p16 area as well as the number of p16 positive cells was able to better discriminate the CIN lesions grades than the usual semi-
quantitative analysis. The average Ki-67 labeling indexes for the normal epithelium, CIN I, CIN II, and CIN III groups were 19.8%, 
27.3%, 32.8%, and 37.1%, respectively, whereas the mean MCM7 labeling indexes for the correspondent grades were 27.0%, 
30.4%, 50.5%, and 67.2%. The Ki-67 and MCM7 labeling indexes were closely correlated with the CIN histological grade, with 
higher labeling indexe values obtained from the more severe lesions (p<0.05), being the MCM7 labeling indexes the highest 
values in all the CIN categories (p<0.05).
Conclusion: We observed a good correlation among the p16, Ki-67, and MCM7 data. In addition, MCM7 demonstrated to be a 
more efficient and sensitive marker to assess disease progression in the uterine cervix.
Keywords: Cervical intraepithelial neoplasia, Genes p16, Immuno-fluorescence analysis, Ki-67 antigen, MCM7 protein
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cells in normal and affected cervical epithelium has not been 
performed.
The proliferative capacity of tumor cells is a fundamental fea-
ture of growing tumors. Ki-67 is a general proliferation marker 
[4] widely used to characterize malignant lesions including 
those of the cervix. The Ki-67 staining into the upper epithe-
lium layers accomplishes the severity of cervical lesions [2,5], 
but the exact nuclear function of Ki-67 antigen is largely un-
known [4]. Thus, detecting markers directly involved in DNA 
replication might be a more precise way to evaluate prolifera-
tive behavior in dysplastic and neoplastic processes. 
Minichromosome maintenance (MCM) proteins (2-7) com-
plex consists of six subunits with essential functions in initia-
tion and elongation of DNA replication [6]. Additionally, it has 
only been demonstrated in replicating cells [7]. 
MCM7 was reported to be associated with tumor formation, 
progression and malignant conversion [8]. It has also been 
considered a valuable proliferation marker in several cancer 
types, such as oral, prostatic, colonic [9], lung-adenocarci-
noma and cervical [8]. Few studies investigated the MCM7 
expression in human cervix tissues [7,8], and there were no 
reports that comparatively evaluated the MCM7 expression 
with those originating from the most commonly used p16 
and Ki-67 markers. The purpose of this study was to compare 
the potential of these three nuclear proteins as biomarkers for 
cervical disease progression.
MATERIALS AND METHODS
1. Tissue samples
Twenty paraffin-embedded cervical samples (5 normal epi-
thelium, 5 CIN I, 5 CIN II, and 5 CIN III cases) were obtained 
from the archive of a large histopathological diagnostic 
service laboratory. This study was approved by the National 
Council of Ethics in Research.
2. Indirect immuno-fluorescence
Serial sections (5 µM-thick) were immersed in xylene, re-
hydrated, heated in water-bath for 30 minutes for antigen 
retrieval, and blocked with 2% phosphate-buffered saline and 
bovine serum albumin (PBS/BSA) for 60 minutes at room tem-
perature (RT). Sections were incubated overnight at 4
oC with 
the primary antibodies: p16 mouse-monoclonal antibody-
clone JC8 (1:800, LabVision, Fremont, CA, USA), Ki-67 rabbit-
polyclonal antibody-clone H-300 (1:100, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and MCM7 mouse-monoclonal 
antibody, clone DCS-141 (1:1000, Abcam, Cambridge, MA, 
USA). Sections were next incubated (1 hour-RT) with second-
ary antibodies: Cy2-Streptavidin-conjugated anti-mouse anti-
body (Molecular-Probes Inc., Eugene, OR, USA) and Cy5-con-
jugated anti-rabbit antibody (Molecular-Probes Inc.), washed, 
mounted (Hydramount, National Diagnostics, Atlanta, GA, 
USA) and examined at high-magnification fields (40x) by scan-
ning confocal microscopy (Carl Zeiss LSM/510Meta, Carl Zeiss 
Jena, Germany).
Strong nuclear and cytoplasmic labeling was considered 
a p16 positive-reaction; the Ki-67/MCM7 markers’ positivity 
was based on strong nuclear labeling detection. Quantitative 
determination of p16 immuno-positive areas and the number 
of positive cells and/or nuclei for all markers was performed 
by the KS-300/Image Analyzer Carl Zeiss. Spearman’s correla-
tion statistical-technique was used for analyzing the associa-
tion between the biomarker’s expression and the cervical-
epithelium histological grade. Pearson’s correlation statistical-
technique was used for comparative-evaluation between p16 
positive cells/nuclei and Ki-67/MCM7 positive nuclei. A p<0.05 
was considered statistically significant. The quantitative results 
were also expressed in a semi-quantitative scale, by using 
previously published scoring-criteria [2]. The Ki-67 and MCM7 
labeling indexes (LIs) were calculated by dividing the number 
of positive nuclei by the total nuclei number [9]. 
RESULTS
Normal tissues did not show any positive areas or immuno-
reactive cells for p16 (Table 1). However an increasing number 
of p16 immuno-labeled areas was observed along with the 
severity of cervical disease (Table 1). A similar result was veri-
fied when these values were expressed in a semi-quantitative 
scale: the majority of CIN I, II, and III samples exhibited a grow-
ing pattern of p16 positive areas (Table 2). In accordance with 
the quantitative p16 area analysis, an increase was observed in 
p16 positive cells according to the CIN severity degree (Table 
1).
However, when these results were semi-quantitatively ex-
pressed the p16 immuno-labeling analysis within the CIN 
groups showed greater variability (Table 2). Regarding the Ki-
67 results, the number of Ki-67 positive nuclei increased from 
normal to CIN II epithelium, but no notable differences were 
observed between CIN II and III values (Table 1). Most normal, 
CIN I and II tissue samples, showed a similar Ki-67 labeling pat-
tern (+2 score), whereas the majority of CIN III samples scored 
as +3. A growing expression of MCM7 was observed from 
normal to CIN III samples, with the highest MCM7 expression 
values detected in CIN III cases (Table 1).
Accordingly, most of normal and all the CIN I samples were MCM7, Ki-67, and p16 as biomarkers tools for CIN progression
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MCM7 scored as +2, while the majority (60%) of CIN II and III 
samples were scored as +3 and +4 (Table 2). The MCM7 LIs ex-
hibited a good correlation with the Ki-67 LIs (p<0.05), and the 
MCM7 labeling-index for each case was considerably higher 
than the corresponding Ki-67 LIs.
The obtained Ki-67 LIs mean values were 19.8 (with samples/
values ranging from 15.8 to 22.5) for the normal epithelium, 
27.31 (range, 8.4 to 33.75) for CIN I-group, 32.84 (range, 22.0 
to 66.2) for CIN II-category, and 37.16 (range, 19.25 to 49.1) for 
CIN III-group (p<0.05). The average MCM7 LIs values for the 
corresponding groups were 27.06 (with values ranging from 
15.1 to 37.6), normal epithelium; 30.36 (range, 20.2 to 36.5), 
CIN I; 50.54 (range, 37.7 to 70.4), CIN II; and 67.26 (range, 39.0 
to 100.0), CIN III; p<0.05.
According to the biomarkers’ expression distribution 
through the cervical epithelium, all the normal cervical tissue 
samples were negative for p16 and showed Ki-67 and MCM7 
labeling in the lower (1/3) basal epithelium (Fig. 1). Forty per-
cent of CIN I samples exhibited p16 immuno-expression in the 
basal layer, while 100% of CIN II and III samples showed label-
ing of 2/3 and 3/3 of the epithelium. Concerning the Ki-67 
expression topology, 60% of CIN I and 100% of CIN II samples 
showed 2/3 of the epithelium staining while 60% of CIN III ex-
hibited labeling in 3/3 of the epithelium. Most of the normal 
and CIN I tissue samples expressed MCM7 in the 1/3 basal-
epithelium, whereas the majority of CIN II and III cases showed 
MCM labeling in 2/3 of the epithelium.
DISCUSSION
In this study we have shown, using a quantitative-evaluation 
approach, that p16, Ki-67, and MCM7 markers are significantly 
correlated with cervical lesion progression. Several studies con-
Table 1. Quantitative mean values of p16 immuno-expression area and the number of p16, Ki-67, and MCM7 positive cells/nuclei according to 
the histo  logi  cal diagnosis
p16 expression area* p16 positive cells Ki-67 positive nuclei MCM7 positive nuclei
Normal 0 0 76.26 
(45.84-114.45)
107.5 
(60.82-179.12)
CIN I 6,668.25
(8,533.26-13,736.0)
122.44
(194.4-215.17)
178.11
(65.47-427.41)
279.25
(134.49-760.42)
CIN II 67,122.46
(57,333.57-77,451.38)
581.83
(445.14-699.52)
220.02
(151.35-360.81)
328.45
(172.53-528.6)
CIN III 88,297.93
(74,615.94-98,388.0)
704.51
(464.75-903.12)
207.18
(155.0-446.21)
546.92
(69.48-1026.0)
Values are presented as number (range). 
MCM, minichromosome maintenance; CIN, cervical intraepithelial neoplasia.
*p16 immuno-positive areas values were expressed in square micrometers (µm
2).
Table 2. Semi-quantitative values of p16 area and the p16, Ki-67, and 
MCM7 cells/nuclei immuno-labeling according to the histological diag-
nosis*
Grading Normal CIN I CIN II CIN III
p16 expression area
†
0 100 40 0 0
+1 0 60 0 0
+2 0 0 100 20
+3 0 0 0 80
p16 positive-cells
†
0 100 40 0 0
+1 0 20 0 0
+2 0 40 0 0
+3 0 0 100 100
Ki-67 positive-nuclei
‡
0 0 0 0 0
+1 40 20 0 20
+2 60 80 80 20
+3 0 0 0 60
+4 0 0 20 0
MCM7 positive-nuclei
‡
0 0 0 0 0
+1 20 0 0 0
+2 80 100 20 20
+3 0 0 60 20
+4 0 0 20 60
MCM, minichromosome maintenance; CIN, cervical intraepithelial 
neoplasia.
*Percentage of samples from each histological diagnosis group exhi-
biting the considered marker expression. 
†Samples were classified as 
0, +1, +2, +3 according to the absence (0) or presence of 5-25%, 25-
75%, and >75% of p16 positive areas and cells. 
‡Samples were scored 
as 0, +1, +2, +3, and +4 when exhibited none, 1-20%, 20-40%, 40-60%, 
and >60% of Ki-67/MCM7 positive nuclei [2].Soraya Lobato, et al.
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firmed negative to minimal p16-staining in normal/reac  tive 
cer  vical biopsies, with considerable variability in the CIN grade 
samples presenting strong p16 immuno-reactivity [1,3]. There-
fore, quantitative analysis of p16 areas and/or cells seemed to 
be a better approach when performing the categorization of 
CIN groups than conventional semi-quantitative evaluation. 
Additionally, we performed a comparative analysis between 
Ki-67 and MCM7 proliferation-related proteins as CIN progres-
sion markers. Ki-67 positivity extending to 2/3 of the epithelium 
was reported to be associated with increasing cervical dysplasia 
degree [2,5]. However, this marker specificity is low [2], Ki-67 
expression-levels can be altered by external factors and there 
is no evidence that this protein is essential for cell proliferation 
[4]. Here, we observed a higher expression of both Ki-67 and 
MCM7 in high-grade when compared to low-grade lesions or 
normal cervical-epithelium. Few studies have examined MCMs 
as proliferation markers in cervical disease and have focused 
mostly in analyzing the MCM2/5 expression. In only one study 
the MCM7 staining topology-pattern was evaluated in cervical, 
normal and affected tissues [8]. Our results are concordant with 
this report, since a significant association between the p16, Ki-67, 
and MCM7 topology-patterns expression and human-cervical 
disease progression was observed. Other reports showed that 
MCM7 labeling-indexes were consistently higher than Ki-67 LIs 
in several cancer types [8,9]. Previous studies have shown that, 
additionally to proliferative cells, MCM proteins were ex  pre  ssed 
in potent or early-proliferating cells [6]. Thus, these observa-
tions may imply that, Ki-67 does not label all proliferating cells 
of some tumors [4].
We believe that MCM7 offers a great advantage over other 
Fig. 1. Comparative immuno-fluore  scent 
analy  sis of Ki-67, p16, and mini  chro  mo-
so  me maintenance 7 (MCM7) markers ex-
pre  ssion in human-cervical tissue-sam  ples 
obtained by loop electrosurgical excision 
procedure (LEEP). The diagnoses were 
independently reviewed/confirmed by 
three certified patho  logists. Positive Ki-
67 and MCM7 cells show fluorescence-
labeling confined to the nu  c  leus (white), 
whereas p16-positive cells show nuclear/
and/cytoplasmic labeling (green). Nuclei 
were immuno-labeled with propidium-
iodide (red). CIN, cervical intraepithelial 
neoplasia.MCM7, Ki-67, and p16 as biomarkers tools for CIN progression
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proliferating biomarkers, since it is not expressed in cells 
undergoing DNA repair [6] and exhibits a higher sensitiv-
ity to identify abnormal precursor cells than Ki-67/PCNA [8]. 
Consequently, MCM7 is regarded an excellent candidate 
marker for cancer screening, surveillance, and prognosis 
[7,9]. In a prospective study involving the analysis of cervical 
smear samples from 455 Indian women, the combined use of 
MCM2/5-staining and Pap-counterstaining disclosed 10 previ-
ously missed cases of biopsy-proven cervical cancer or pre-
cancer when using the standard Pap-staining [10]. Although 
this study was focused on the evaluation of MCM7 as an 
indicator of progressive-cervical disease in tissue samples, the 
biomarker expression demonstrated a satisfactory correlation 
with CIN progression, suggesting that MCM7 could be used as 
a valuable tool for improving the diagnosis and screening of 
pre-malignant lesions and cervical cancer. 
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